Conference Reports for NATAP

Back

Tweet

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs Virtual Meeting, September 28-30, 2020     Ledipasvir Exposure Linked to SVR, But Overall Response Rate High - By Mark Mascolini for NATAP and Virology Education (10/01/20)   Neonatal Liquid Dolutegravir Comparable to Pediatric Dispersible Tablets - By Mark Mascolini for NATAP and Virology Education (10/01/20)   Comparison of Relative Bioavailability of TIVICAY Neonatal Liquid Formulations to Pediatric Dispersible Tablets - (10/01/20)   Population pharmacokinetic (PopPK) modeling and simulation of monthly intramuscular (IM) long-acting rilpivirine (RPV LA) to inform strategies following dosing interruptions in HIV-1 infected subjects - (10/01/20)   No Interactions Between HIV-1 Maturation Inhibitor and TAF/FTC - By Mark Mascolini for NATAP and Virology Education (09/30/20)   No Interactions Between HIV-1 Maturation Inhibitor and TAF/FTC - By Mark Mascolini for NATAP and Virology Education (09/30/20)   Levels of Long-Acting Anti-HIV bNAb High in Infants After 1 or 2 Doses--But Not High Enough - By Mark Mascolini for NATAP and Virology Education (09/30/20)   Model Predicts Long-Acting IM Rilpivirine Safe With Liver Impairment - By Mark Mascolini for NATAP and Virology Education (09/30/20)   Antiretroviral Drug-Drug Interaction Profile of Long-Acting Cabotegravir and Rilpivirine - (09/30/20)   Three Phase I Drug Interaction Studies Investigating the Next-Generation Maturation Inhibitor GSK3640254 With Oral Contraceptive Ethinyl Estradiol/Levonorgestrel, Dolutegravir, and Tenofovir Alafenamide/Emtricitabine - (09/30/20)   Dolutegravir (DTG) plasma concentrations under different combinations regimens for ART-pre-treated adults living with HIV - (09/30/20)   FOSTEMSAVIR DRUG-DRUG INTERACTION PROFILE, AN ATTACHMENT INHIBITOR AND ORAL PRODRUG OF TEMSAVIR, FOR PATIENTS WITH MULTIDRUG-RESISTANT HIV-1 INFECTION - (09/30/20)   No Adverse Pregnancy Outcome Patterns With Common Antiretrovirals - By Mark Mascolini for NATAP and Virology Education (09/30/20)   PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF DOLUTEGRAVIR/RILPIVIRINE (JULUCA) IN HEALTHY JAPANESE ADULTS - (09/28/20)   THE PHARMACOKINETICS (PK) OF DOVATO (50 MG DOLUTEGRAVIR [DTG]/ 300 MG LAMIVUDINE [3TC]) FIXED-DOSE COMBINATION IN HIV-INFECTED PATIENTS - (09/28/20)   TFV Levels Far Lower in Milk Than Plasma With Dried Milk and Blood Spots - Mark Mascolini - (09/28/20)   FTC Exposure Higher in Young Transgender Men Than Cisgender Controls - Mark Mascolini - (09/28/20)